Rockwell Medical Inc
NASDAQ:RMTI
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Rockwell Medical Inc
NASDAQ:RMTI
|
44.1m USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.3T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57.9B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
120B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
11.4B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.2B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.1B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.4T KRW |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Rockwell Medical Inc
Glance View
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 300 full-time employees. The firm is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. The company is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The firm has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Rockwell Medical Inc is -7.3%, which is in line with its 3-year median of -7.3%.
Over the last 3 years, Rockwell Medical Inc’s Net Margin has increased from -36.7% to -7.3%. During this period, it reached a low of -36.7% on Sep 30, 2022 and a high of -0.3% on Mar 31, 2025.
